poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42

Benzinga Newsdesk

HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and lowers the price target from $45 to $42.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VTVT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    vTv Therapeutics to Participate in September Investor Conferences

    vTv Therapeutics announced that management will participate in two investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference on September 16 and the 5th Annual ROTH Healthcare Opportunities Conference on September 29. The company continues advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes, with its Phase 3 CATT1 trial expected to complete enrollment in Q3 2026.

    VTVT
  2. Benzinga Newsdesk

    vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate

    vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 14.13 percent decrease over losses of $(0.92) per share

    VTVT